๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 36 Beijing 20 Guangzhou 11 Tianjin 11 Jinan 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University454 Ruijin Hospital276 Shanghai Zhongshan Hospital163 RenJi Hospital135 Children's Hospital of Fudan University84 Clear sponsor filter
Site location
Shanghai36 Beijing20 Guangzhou11 Tianjin11 Jinan6
All 24 locations
Target enrolment
to

Trials with a site in Shanghai

36 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors
NCT07806058Pancreatic Cancer
DrugsHRS-7172·HRS-4642·Adebrelimab
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
140
Shanghai
2026-09
Recruiting
A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer
NCT07711184Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
320
Shanghai
2026-07-30
Recruiting
A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery
NCT06529432Local Analgesia Via Nerve Block
DrugsBupivacaine liposome·Bupivacaine hydrochloride
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
96
Shanghai
2026-03-03
Recruiting
The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia
NCT07362355Primary Gout and Hyperuricemia
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
340
Shanghai
2026-02-09
Recruiting
A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
NCT07311694PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
370
Shanghai
2026-02-02
Recruiting
A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT07232849Lung Cancer
DrugHRS-4508
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
100
Shanghai, Hangzhou
2025-12-04
Recruiting
HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer
NCT07232875KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
588
Shanghai
2025-11-21
Active, closed
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
NCT07196774Early-stage or Locally Advanced HER2-positive Breast Cancer
DrugsPertuzumab·Trastuzumab Rezetecan·Trastuzumab·Docetaxel
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
740
Shenyang, Shanghai
2025-10-23
Recruiting
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
NCT07136142Malignant Solid Tumor
DrugFH-006
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
150
Shanghai, Tianjin
2025-09-23
Recruiting
Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations
NCT07134998Advanced KRAS G12D Mutant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
153
Shanghai, Chengdu
2025-09-16
Recruiting
A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
NCT07142980Advanced Solid Tumors Harboring RAS Mutations or Amplifications
DrugHRS-7172
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
120
Shanghai
2025-09-12
Recruiting
A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT07003321Solid Tumor
DrugHRS-4508
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
120
Shanghai
2025-09-12
Active, closed
A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
NCT07018453Type 2 Diabetes Mellitus
DrugsSHR-3167·Insulin Degludec
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
173
Chongqing, Shanghai
2025-07-16
Recruiting
A Trial of HRS-6768 in Patients With Advanced Solid Tumors
NCT06925581Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
84
Beijing, Shanghai
2025-04-24
Recruiting
A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
NCT06569056Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
DrugHRS-8427
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
578
Shanghai
2024-09-25
Recruiting
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
NCT06568094Prostate Cancer
DrugsAbiraterone Acetate ๏ผˆII๏ผ‰·HRS-6208·HRS-2189·HRS-1167
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
100
Harbin, Shanghai
2024-09-25
Recruiting
A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients
NCT06555068Advanced Unresectable or Metastatic Breast Cancer
DrugsHRS-1358·HRS-6209·HRS-8080·Letrozole
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
528
Shanghai
2024-08-12
Recruiting
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
NCT06520488Advanced Solid Tumors
DrugHRS-4642
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
118
Shanghai
2024-08-09
Recruiting
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
NCT06430437Non-Small Cell Lung Cancer With HER2- Mutations
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
300
Shanghai
2024-07-29
Active, closed
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
NCT06385678Advanced KRAS G12D Mutant Solid Tumors
DrugsSHR-9839·HRS-4642·Cetuximab·Adebrelimab
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
47
Shanghai
2024-07-05
Active, closed
Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
NCT06413745HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
59
Shanghai
2024-06-04
Active, closed
Randomized, Double-blind, Placebo-controlled Study of RSS0393 Ointment in Healthy and Psoriatic Subjects
NCT06308393Healthy, Psoriatic Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
98
Hefei, Shanghai
2024-03-01
Recruiting
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
NCT06123494HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
360
Shanghai
2024-01-09
Active, closed
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
NCT06126640HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
DrugsTrastuzumab emtansine·Trastuzumab Rezetecan
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
1,615
Shanghai, Tianjin
2023-11-20
Recruiting
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05942001Advanced Prostate Cancer
DrugsEnzalutamide Soft·HRS-5041·Prednisone Acetate·Abiraterone acetate
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
100
Shanghai
2023-08-03
Recruiting
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
NCT05884255Advanced Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
220
Shanghai, Tianjin
2023-07-06
Active, closed
A Phase I Clinical Study of the Safety๏ผŒ Tolerability๏ผŒPharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
NCT05781048Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
56
Shanghai
2023-03-23
Active, closed
Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
NCT05533463Advanced KRAS G12D Mutant Solid Tumors
DrugHRS-4642
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
102
Shanghai
2022-09-21
Recruiting
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
NCT05482568Advanced Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
324
Shanghai, Hangzhou
2022-09-15
Active, closed
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
NCT05320692Hepatocellular Carcinoma
DrugsTACE·Apatinib Mesylate·Camrelizumab
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
423
Shanghai
2022-08-09
Active, closed
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
NCT04906993Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
443
Shanghai
2021-07-23
Active, closed
Phase III Study ๏ผšSHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative
NCT04842617Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage๏ผŒFemale Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
5,274
Shanghai
2021-04-30
Active, closed
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
NCT04639180Hepatocellular Carcinoma (HCC)
DrugsRivoceranib·Apatinib·Camrelizumab
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
687
Chongqing, Nanjin, Guiyang, Shanghai, Tianjin
2021-04-01
Active, closed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04691804Metastatic Castration-Resistant Prostate Cancer (mCRPC)
DrugFluzoparib
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
Shanghai, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang
2021-03-18
Recruiting
A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
NCT04316364Non-Small-Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
537
Beijing, Guangzhou, Zhengzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2020-07-14
Active, closed
A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
NCT03980054Breast Cancer
DrugPyrotinib
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
2,135
Shanghai
2019-07-12
Rows per page Showing 1–36 of 36
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 36 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

21 of the 36 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 14 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 36 studies
PhaseStudiesRecruitingShare
Phase 315741.7%
Phase 1/28622.2%
Phase 17419.4%
Phase 26416.7%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Jiangsu HengRui Medicine Co., Ltd.3621
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.